April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Roundtable Discussion: Abou-Alfa Evaluates Choice of Therapy for HCC Based on Patient Factors
August 25th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.
Read More
Pembrolizumab Plus Lenvatinib Misses Primary End Points in Unresectable HCC
August 5th 2022While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.
Read More
Cabozantinib Plus Atezolizumab Improved Progression-Free Survival in Patients with HCC Vs Sorafenib
July 21st 2022In COSMIC-312, reduction in the risk of disease progression or death was achieved with the combination of cabozantinib Plus atezolizumab compatient with sorafenib in patient with hepatocellular carcinoma.
Read More
Finn Reviews Options and Dosing for a Patient With Unresectable HCC
June 21st 2022During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.
Read More
Viral Etiology, NLR Lead to Better Responses With Atezolizumab/Bevacizumab Combo in HCC
March 23rd 2022Treatment with atezolizumab plus bevacizumab in the first-line setting achieved better responses for patients with unrespectable hepatocellular carcinoma when their disease had a viral versus nonviral etiology and neutrophil-to-lymphocyte ratio was less than 3.6.
Read More